Anti-HER2 therapy with pyrotinib and trastuzumab in refractory HER2-positive metastatic colorectal cancer: A preliminary report from HER2-FUSCC-G study. This is an ASCO Meeting Abstract from the 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results